Produção Nacional
Revisado por pares
Strategies to manage hepatitis C virus ( HCV ) disease burden
2014; Wiley; Volume: 21; Issue: s1 Linguagem: Inglês
10.1111/jvh.12249
ISSN1365-2893
AutoresHeiner Wedemeyer, A.‐S. Duberg, Marı́a Buti, William Rosenberg, Soňa Fraňková, Gamal Esmat, Necati Örmecı, Hans Van Vlierberghe, Michael Gschwantler, Ulus Salih Akarca, Soo Aleman, İsmail Balık, Thomas Berg, Florian Bihl, Marc Bilodeau, Antonio Javier Blasco, Carlos Eduardo Brandão‐Mello, Philip Bruggmann, Filipe Calinas, José Luís Calleja, Hugo Cheinquer, Peer Brehm Christensen, Mette Rye Clausen, Henrique Sérgio Moraes Coelho, Markus Cornberg, Matthew Cramp, Gregory J. Dore, Wahid Doss, Manal H. El‐Sayed, Gül Ergör, Chris Estes, Karolin Falconer, J Félix, Maria Lúcia Gomes Ferraz, Paulo Roberto Abrão Ferreira, Javier García‐Samaniego, Jan Gerstoft, José Gíria, Fernando Lopes Gonçales, Mário G. Pessôa, Christophe Hézode, S. J. Hindman, Heribert Hofer, Petr Husa, Ramazan İdilman, Martin Kåberg, Kelly Kaita, Achim Kautz, Sabahattin Kaymakoğlu, Mel Krajden, Henrik Krarup, Wim Laleman, Daniel Lavanchy, Pablo Lázaro, Rui Tato Marinho, Paul Marotta, Stefan Mauss, Maria Cássia Mendes Corrêa, Christophe Moreno, Beat Müllhaupt, Robert P. Myers, Vratislav Němeček, Anne Øvrehus, Julie Parkes, Kevork Peltekian, Alnoor Ramji, Homie Razavi, Nathalia Rodrigues dos Reis, Stuart K. Roberts, Françoise Roudot‐Thoraval, Stephen Ryder, Rui Sarmento‐Castro, Christoph Sarrazin, David Semela, Morris Sherman, Gamal Shiha, Jan Šperl, Peter Stärkel, Rudolf Stauber, A. Thompson, Petr Urbánek, Pierre Van Damme, Ingo van Thiel, Dominique Vandijck, W. Vogel, Imam Waked, Nina Weis, Johannes Wiegand, A. Yosry, Amany Zekry, Francesco Negro, William Sievert, E. Gower,
Tópico(s)Liver Disease and Transplantation
ResumoSummary The number of hepatitis C virus ( HCV ) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV ‐related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3–5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
Referência(s)